Publications by authors named "Phillipe Aftimos"
Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.
Aditya Bardia Javier Cortés François-Clément Bidard Patrick Neven José Garcia-Sáenz Phillipe Aftimos
Clin Cancer Res
October 2024
Article Synopsis
- Elacestrant, a treatment for estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer, showed significantly longer progression-free survival (PFS) compared to standard endocrine therapy (SOC) for patients with ESR1 mutations who had previously received ET plus CDK4/6 inhibitors.
- In a phase III trial named EMERALD, patients were randomly assigned to receive either elacestrant or SOC, and the results indicated that those with ESR1 mutations and prior ET plus CDK4/6i usage of 12 months or more had a notably longer median PFS with elacestrant (8.6 months) versus SOC (1.9 months).
- The observed benefits of elacestrant